Therapeutic efficacy of recombinant human growth hormone in children with different etiologies of dwarfism from a pharmacoeconomic point of view
Open Access
- 21 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (25) , e38350
Abstract
Treatment outcomes for different causes of childhood dwarfism vary widely, and there are no studies on the economic burden of treatment in relation to outcomes. This paper compared the efficacy and healthcare costs per unit height of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD) and idiopathic short stature (ISS) with a view to providing a more cost-effective treatment option for children. We retrospectively analyzed 117 cases (66 cases of GHD and 51 cases of ISS) of short-stature children who first visited Weifang People’s Hospital between 2019.1 and 2022.1 and were treated with rhGH for 1 to 3 years to track the treatment effect and statistically analyzed by using paired t tests, non-parametric tests, and chi-square tests, to evaluate the efficacy of rhGH treatment for GHD and ISS children and the medicinal cost. The annual growth velocity (GV) of children with GHD and ISS increased the fastest during 3 to 6 months after treatment and then gradually slowed down. The GV of the GHD group was higher than that of the ISS group from 0 to 36 months after treatment (P < .05 at 3, 6, 9, and 12 months); the height standard deviation scores (HtSDS) of the children in the GHD and ISS groups increased gradually with the increase of the treatment time, and the changes in the height standard deviation scores (ΔHtSDS) of the GHD group were more significant than those of the ISS group (P < .05 at 3, 6, 9, and 12 months). (2) The medical costs in the pubertal group for a 1-cm increase in height were higher than those of children in the pre-pubertal group at the same stage (3 to 24 months P < .05). The longer the treatment time within the same group, the higher the medical cost of increasing 1cm height. RhGH is effective in treating children with dwarfism to promote height growth, and the effect on children with GHD is better than that of children with ISS; the earlier the treatment time, the lower the medical cost and the higher the comprehensive benefit.Keywords
This publication has 19 references indexed in Scilit:
- A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature ChildrenHealth Care Analysis, 2020
- Pathogenic/likely pathogenic variants in theSHOX,GHRandIGFALSgenes among Indian children with idiopathic short statureJournal of Pediatric Endocrinology and Metabolism, 2019
- First-year predictors of health-related quality of life changes in short-statured children treated with human growth hormoneJournal of Endocrinological Investigation, 2019
- Efficacy and safety of recombinant human growth hormone in treating Chinese children with idiopathic short statureGrowth Hormone & IGF Research, 2018
- Growth Hormone Treatment for Idiopathic Short Stature.2018
- Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidenceCurrent Opinion in Pediatrics, 2017
- Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient childrenJournal of Pediatric Endocrinology and Metabolism, 2017
- Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I DeficiencyHormone Research in Paediatrics, 2016
- Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefitInternational Journal of Pediatric Endocrinology, 2014
- Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic reviewBMJ, 2011